Siglec-2/CD22 Products

Siglec-2/CD22 Antibody (2H1C4 ...
Siglec-2/CD22 Antibody (2H1C4)
Applications: WB, ELISA, Flow, ICC/IF, IHC, IHC-P
Host: Mouse Monoclonal
Human Siglec-2/CD22 DuoSet EL ...
Human Siglec-2/CD22 DuoSet ELISA, ...
Applications: ELISA
Recombinant Human Siglec-2/CD ...
Recombinant Human Siglec-2/CD22 Fc...
Species: Hu
Applications: Bioactivity
Formulation Catalog # Availability Price  
Recombinant Mouse Siglec-2/CD ...
Recombinant Mouse Siglec-2/CD22 Fc...
Species: Mu
Applications: Bioactivity
Formulation Catalog # Availability Price  
Recombinant Human Siglec-2/CD ...
Recombinant Human Siglec-2/CD22 Hi...
Species: Hu
Applications: Bioactivity
Conjugate Catalog # Availability Size Price
Formulation Catalog # Availability Price  


CD22 is a single-pass type 1 membrane glycoprotein found in the cytoplasm and cell membrane of B-lymphocytes. CD22 has at least two isoforms (alpha and beta) produced by alternate splicing. The protein exists predominantly as a monomer of the beta isoform (95 kDa). It is also found as a heterodimer of the beta and alpha isoforms.


Entrez Human
Uniprot Human
Product By Gene ID 933
Alternate Names
  • B-lymphocyte cell adhesion molecule
  • Siglec-2
  • BL-CAM
  • sialic acid binding Ig-like lectin 2
  • Sialic acid-binding Ig-like lectin 2
  • B-cell receptor CD22
  • SIGLEC-2
  • CD22 antigenMGC130020
  • SIGLEC2FLJ22814
  • T-cell surface antigen Leu-14
  • CD22 molecule

Research Areas for Siglec-2/CD22

Find related products by research area and learn more about each of the different research areas below.

Adaptive Immunity
CD Markers
DNA Repair

Bioinformatics Tool for Siglec-2/CD22

Discover related pathways, diseases and genes to Siglec-2/CD22. Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Vizit™, under license from BioVista Inc.

Related Siglec-2/CD22 Blog Posts

Check out the latest blog posts on Siglec-2/CD22.
Antigen-loss relapse after successful CAR-T therapy; What do we do now?
By Jacqueline Carrico, BS, MD Tumor cell mechanisms driving tolerance to CAR-T Despite very promising results of CAR-T therapy in acute lymphoblastic leukemia, B-ALL, antigen-loss relapse has arisen as a major chall...    Read more.
Read more Siglec-2/CD22 related blogs.